Stifel analyst Laura Prendergast initiated coverage of BridgeBio Oncology (BBOT) with a Buy rating and $23 price target The firm says the company is in the “sweet” spot by targeting RAS and PI3K alpha, the two most commonly mutated oncogenes. BridgeBio is well positioned into its second half of 2026 catalysts following January’s “early de-risking data” and a cash runway into 2028, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBOT:
- BridgeBio Oncology initiated with an Outperform at Raymond James
- BridgeBio Oncology price target lowered to $18 from $20 at Morgan Stanley
- Reaffirming Buy on BridgeBio Oncology: Differentiated KRASG12C Profile, Strong Early Efficacy, and Broad Keytruda Combination Potential
- BridgeBio Oncology reports promising RAS and PI3Kα data
- BridgeBio Oncology announces new clinical data across 3 pipeline programs